Holen Sie sich die Stockscreener-App
2.36
2.07%
-0.05
Handel nachbörslich:
2.35
-0.010
-0.42%
Schlusskurs vom Vortag:
$2.41
Offen:
$2.41
24-Stunden-Volumen:
153.10K
Relative Volume:
1.71
Marktkapitalisierung:
$96.77M
Einnahmen:
$2.70M
Nettoeinkommen (Verlust:
$5.53M
KGV:
21.45
EPS:
0.11
Netto-Cashflow:
$-10.55M
1W Leistung:
-4.84%
1M Leistung:
-2.07%
6M Leistung:
+3.96%
1J Leistung:
-0.84%
1-Tages-Spanne:
$2.32
$2.43
1-Wochen-Bereich:
$2.31
$2.50
52-Wochen-Spanne:
$1.82
$3.09
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Firmenname
Oramed Pharmaceuticals Inc
Sektor
Branche
Telefon
646-844-1164
Adresse
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Vergleichen Sie ORMP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
2.36 | 98.82M | 2.70M | 5.53M | -10.55M | 0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-12 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-09 | Eingeleitet | National Securities | Buy |
| 2020-12-03 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-11 | Eingeleitet | Aegis Capital | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-12-11 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | Bestätigt | FBR Capital | Outperform |
| 2015-12-01 | Bestätigt | H.C. Wainwright | Buy |
| 2015-11-19 | Eingeleitet | FBR Capital | Outperform |
| 2015-04-13 | Fortgesetzt | MLV & Co | Buy |
| 2014-01-30 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Eingeleitet | MLV & Co | Buy |
| 2013-12-03 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Oramed Pharmaceuticals Inc Aktie (ORMP) Neueste Nachrichten
Will Oramed Pharmaceuticals Inc. stock go up soon2025 Breakouts & Breakdowns & Technical Pattern Based Signals - newser.com
Visualizing Oramed Pharmaceuticals Inc. stock with heatmaps2025 AllTime Highs & Verified Chart Pattern Trade Signals - newser.com
Will Oramed Pharmaceuticals Inc. stock outperform Dow Jones indexWeekly Investment Recap & Weekly Watchlist of Top Performers - newser.com
Wealth Enhancement Advisory Services LLC Purchases 5,000 Shares of Oramed Pharmaceuticals Inc. $ORMP - Defense World
Exit strategy if you’re trapped in Oramed Pharmaceuticals Inc.2025 EndofYear Setup & Verified Trade Idea Suggestions - newser.com
Oramed Pharmaceuticals Forms Golden Cross, Signaling Bullish Breakout Ahead - Markets Mojo
Oramed Pharmaceuticals Inc. stock outlook for YEARStop Loss & Expert Verified Movement Alerts - newser.com
What’s the recovery path for long term holders of Oramed Pharmaceuticals Inc.2025 Technical Overview & Real-Time Buy Signal Alerts - newser.com
Weiss Ratings Reaffirms Sell (D) Rating for Oramed Pharmaceuticals (NASDAQ:ORMP) - MarketBeat
Analyzing recovery setups for Oramed Pharmaceuticals Inc. investorsGold Moves & Free AI Powered Buy and Sell Recommendations - newser.com
How to track smart money flows in Oramed Pharmaceuticals Inc.July 2025 Pullbacks & Weekly Market Pulse Updates - newser.com
Is Oramed Pharmaceuticals Inc. stock affected by interest rate hikesWeekly Trade Summary & AI Optimized Trading Strategy Guides - newser.com
How supply chain issues affect Oramed Pharmaceuticals Inc. stockJuly 2025 Levels & Low Drawdown Momentum Ideas - newser.com
Is Oramed Pharmaceuticals Inc OJU1 a good long term investmentPrice Volatility Patterns & Free Double Digit Growth Tips - earlytimes.in
What analysts say about Oramed Pharmaceuticals Inc stockEarnings Season Recap & Small Budget Wealth Building - earlytimes.in
Oramed Pharmaceuticals completes first tranche of Scilex warrant repurchase - Investing.com
Oramed Pharm Completes Warrant Repurchase Agreement - TipRanks
How to forecast Oramed Pharmaceuticals Inc. trends using time seriesQuarterly Earnings Summary & Community Supported Trade Ideas - newser.com
What MACD signals say about Oramed Pharmaceuticals Inc.Weekly Trade Recap & Intraday High Probability Alerts - newser.com
Can Oramed Pharmaceuticals Inc. (OJU1) stock withstand sector downturnsSell Signal & Safe Entry Point Identification - newser.com
Can Oramed Pharmaceuticals Inc. stock attract ESG capital inflowsEarnings Risk Report & Free Community Supported Trade Ideas - newser.com
What institutional flow reveals about Oramed Pharmaceuticals Inc.2025 Market Overview & Free Accurate Trade Setup Notifications - newser.com
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Down 35.7% in September - MarketBeat
Will Oramed Pharmaceuticals Inc. bounce back from current supportWeekly Volume Report & Verified Stock Trade Ideas - newser.com
Can Oramed Pharmaceuticals Inc. stock deliver surprise earnings beatMarket Movers & Fast Exit Strategy with Risk Control - newser.com
Has Oramed Pharmaceuticals Inc. found a price floorJuly 2025 Pullbacks & Real-Time Chart Pattern Alerts - newser.com
Analyzing net buyer seller activity in Oramed Pharmaceuticals Inc.Buy Signal & Technical Pattern Based Signals - newser.com
Using RSI to spot recovery in Oramed Pharmaceuticals Inc.2025 Short Interest & Real-Time Volume Triggers - newser.com
Will Oramed Pharmaceuticals Inc. stock see PE expansionTrade Analysis Summary & Daily Profit Maximizing Tips - newser.com
Finanzdaten der Oramed Pharmaceuticals Inc-Aktie (ORMP)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):